Clinical Trials

Twitter

Facebook

Copy Link

Key Facts

Use CasesPatient Matching, Site Selection

Key PlayersTempus, Unlearn.ai, Medidata

Top News

AstraZeneca and Oracle Partner to Accelerate Patient Recruitment Using AI in Clinical Trials

AstraZeneca has partnered with Oracle to deploy AI and real patient health data in clinical trials, aiming to speed up patient recruitment and improve drug safety monitoring. The first project launches in Abu Dhabi with M42, targeting uncontrolled hypertension, with plans to expand across cancer, heart disease, and rare diseases in the US, Middle East, and Europe.

Technology3 sources

AstraZeneca and Oracle Partner to Accelerate Patient Recruitment Using AI in Clinical Trials

Technology3 sources

Zealand Pharma and Generate Biomedicines forge $1.2 billion AI drug partnership for obesity treatments

Zealand Pharma and Generate Biomedicines announced a strategic collaboration worth up to $1.2 billion to develop AI-engineered protein therapies for obesity and metabolic diseases. Generate will receive $30 million upfront and leverage its generative AI platform for drug discovery, while Zealand Pharma will handle clinical development and commercialization of the protein therapeutics.

Business5 sources

Zealand Pharma and Generate Biomedicines forge $1.2 billion AI drug partnership for obesity treatments

Business5 sources

Google's AMIE Chatbot Shows Promise in First Real-World Clinical Trial for AI in Healthcare

Google's AMIE chatbot successfully completed an 8-month clinical trial at Beth Israel Deaconess Medical Center, helping doctors prepare for 75% of patient visits. The AI diagnostic chatbot matched final diagnoses 90% of the time and hallucinated only once across 98 patient interactions, marking a significant step for patient-facing conversational AI in urgent care settings.

Health4 sources

Google's AMIE Chatbot Shows Promise in First Real-World Clinical Trial for AI in Healthcare

Health4 sources

First Patient Treated in Groundbreaking Armored CAR T-Cell Therapy Trial for Ovarian Cancer

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a clinical trial evaluating GB-5267, an AI-designed IL-18 armored CAR T-cell therapy targeting MUC16 in recurrent ovarian cancer. The treatment aims to overcome immune suppression without requiring chemotherapy-based lymphodepletion.

Health2 sources

First Patient Treated in Groundbreaking Armored CAR T-Cell Therapy Trial for Ovarian Cancer

Health2 sources

MIT Engineers Use AI to Develop Heat-Resistant RNA Vaccines Stable at Room Temperature

MIT researchers have developed heat-resistant RNA vaccine formulations using an AI algorithm that can remain stable at room temperature for up to a year. The breakthrough addresses a major distribution challenge by eliminating the need for ultracold storage, potentially enabling wider vaccine access globally.

Health2 sources

MIT Engineers Use AI to Develop Heat-Resistant RNA Vaccines Stable at Room Temperature

Health2 sources

Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Into Clinical Trials

Biotech startup Enveda closed a $311 million Series E at a $2 billion valuation to advance AI-discovered drug candidates targeting severe skin conditions, weight loss maintenance, and inflammatory diseases. The Boulder-based company has moved three nature-derived compounds into human trials using its PRISM platform.

Startups2 sources

Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Into Clinical Trials

Startups2 sources

Nvidia-Backed AI Drug Discovery Startup Iambic Therapeutics Files for Nasdaq IPO

Iambic Therapeutics, an AI drug discovery company backed by Nvidia and Qatar Investment Authority, filed for a Nasdaq IPO to advance three cancer drug candidates. The San Diego-based biotech has raised $461.8 million and uses its molecular superintelligence platform to develop treatments for solid tumors.

Business4 sources

Nvidia-Backed AI Drug Discovery Startup Iambic Therapeutics Files for Nasdaq IPO

Business4 sources

AI Agents Transform Drug Discovery: 37,000 Virtual Scientists Identify Cancer Treatments

Stanford researchers deployed 37,000 AI agents organized as a Virtual Biotech company to accelerate drug discovery. The AI co-scientists autonomously analyzed over 55,000 clinical trials and identified a promising lung cancer treatment targeting CD276 protein. Google's Co-Scientist system proposed novel cancer-fighting strategies by analyzing 700+ papers, demonstrating AI's role in scientific breakthrough.

Technology3 sources

AI Agents Transform Drug Discovery: 37,000 Virtual Scientists Identify Cancer Treatments

Technology3 sources

Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

Insilico Medicine announced Longevity Vaccines, a research initiative using AI-driven drug discovery to develop single-dose therapies that eliminate senescent cells. The programmable circular RNA platform targets cellular drivers of age-related diseases, starting with immunosenescence. The company reported $106 million revenue in H1 2026, marking its first profitable half-year.

Health2 sources

Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

Health2 sources

AI Tool Achieves 91% Accuracy Predicting Lung Cancer Immunotherapy Outcomes Across Global Study

Two breakthrough studies demonstrate how AI tools are transforming lung cancer treatment decisions. An AI algorithm achieved 91% accuracy in assessing pathologic response to neoadjuvant chemoimmunotherapy in NSCLC patients, while the I3LUNG project's AI models outperformed standard biomarkers in predicting immunotherapy outcomes across 2,396 patients from six international centers.

Health3 sources

AI Tool Achieves 91% Accuracy Predicting Lung Cancer Immunotherapy Outcomes Across Global Study

Health3 sources

AI-Designed Drug Rentosertib Reverses Biological Age by 3-4 Years in Clinical Trial

Insilico Medicine's rentosertib, an AI-generated drug for lung disease, reduced biological age markers by 3-4 years across six proteomic aging clocks in a 42-patient Phase IIa trial. Published in Nature Biotechnology, the study marks the first clinical evaluation of a drug featuring both an AI-discovered target and AI-designed molecule for aging and disease biology.

Health10 sources

AI-Designed Drug Rentosertib Reverses Biological Age by 3-4 Years in Clinical Trial

Health10 sources

Indian Startup Dognosis Uses AI to Train Dogs for Cancer Detection with 90% Accuracy

Bengaluru-based startup Dognosis is pioneering AI-assisted cancer detection using trained dogs equipped with sensor-fitted helmets. A study involving more than 1,500 participants across six hospitals reported over 90% accuracy in detecting seven cancer types through breath samples, though oncologists stress the need for larger independent trials before clinical deployment.

Health4 sources

Indian Startup Dognosis Uses AI to Train Dogs for Cancer Detection with 90% Accuracy

Health4 sources

AI Reads ECG in Under 2 Seconds, Detects Heart Disease Clinicians Miss

Researchers at Imperial College London unveiled an AI system that analyzes ECGs in under two seconds, identifying heart failure and valve disease with up to 81% and 90% accuracy respectively. Trained on 1.6 million recordings, the tool extracts signals clinicians cannot detect, potentially fast-tracking high-risk patients for treatment and addressing months-long wait times for echocardiograms.

Health3 sources

AI Reads ECG in Under 2 Seconds, Detects Heart Disease Clinicians Miss

Health3 sources

First AI-Assisted Brain Tumor Operation Saves Patient's Sight at London Hospital

Surgeons at London's National Hospital for Neurology and Neurosurgery successfully removed an 11mm pituitary gland tumor using real-time AI assistance for the first time. The system analyzed live surgical footage to identify critical anatomy, helping protect 48-year-old Rhys Hibbert's vision during the high-risk medical procedure.

Health10 sources

First AI-Assisted Brain Tumor Operation Saves Patient's Sight at London Hospital

Health10 sources

Hair-Like Soft Robot Captures Tumor Cells From All 23 Liver Cancer Patients Tested

Scientists developed CiliaVine, a tiny hairy robot that manipulates blood flow using magnetic fields. The device captured circulating tumor cells from all 23 liver cancer patients tested and sped up blood clot dissolution by 43% in lab models. Researchers from Shenzhen and Hong Kong say the soft robot could transform targeted drug delivery and cancer monitoring.

Health2 sources

Hair-Like Soft Robot Captures Tumor Cells From All 23 Liver Cancer Patients Tested

Health2 sources

Prev12 3 4 Next